![malvern zetasizer graphene analyses malvern zetasizer graphene analyses](https://storage.googleapis.com/bioz_article_images/PMC8119986/41598_2021_89376_Fig1_HTML.jpg)
Sinemet is now the most common drug prescribed to Parkinson's disease patients, and Sinemet and other Parkinson's disease drugs do not function to fundamentally treat or delay the disease but supply Levodopa (L-DOPA) which is converted into dopamine in neurons to temporally reduce the symptoms.
![malvern zetasizer graphene analyses malvern zetasizer graphene analyses](https://www.umass.edu/ials/sites/default/files/malvern-zetasizer-nanozsp.png)
As for Parkinson's disease, the disease progresses while neurons that produce a neurotransmitter called dopamine are gradually necrosed. Fibrillated proteins are gradually transmitted to adjacent neurons and finally necrose all the neurons in a specific part of the brain, so that the specific part cannot perform its functions. That is, malfunction of proteostasis causes protein misfolding and its intracellular abnormal accumulation.Īll the causes of neurodegenerative diseases have not yet been found, but it has been well known that aggregation of neuronal proteins is a main cause.
![malvern zetasizer graphene analyses malvern zetasizer graphene analyses](https://www.ifsc.usp.br/gryphon_mals/malvern.png)
It has been known that protein misfolding causes normal proteins to lose their function and abnormal proteins to be accumulated in cells and produce toxicity and thus causes various diseases such as Alzheimer's disease, Parkinson's disease, Huntington's chorea, Lou Gehrig's disease, cancer, cystic fibrosis, and type II diabetes. The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases, the pharmaceutical composition including a graphene nanostructure as an active ingredient.